RxDoctor Payments Data

Pia Cobrado, APRN

Nurse Practitioner · Plymouth, MANPI 1851017024

Payments from drug & device makers

$1,745in general payments, 2019–2025

Across 20 payments — averaging $87.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$460
  • Sobi, Inc$273
  • Lilly USA, LLC$214
  • Regeneron Healthcare Solutions, Inc.$182
  • Genentech USA, Inc.$139
  • Johnson & Johnson$127
  • plus $350 from 4 others

What the payments were for

  • Food & beverage$1,54789%
  • Education$19811%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,745 in reported general payments places this provider in the 90th percentile of 3,855 nurse practitioner providers in Massachusetts.

See all nurse practitioner providers in Massachusetts

Medicare billing

Part B allowed, 2024
$8,975
Medicare patients
61
Services billed
97

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide19$316,502
CalquenceAcalabrutinib Maleate15$267,649
JakafiRuxolitinib Phosphate11$197,869
EliquisApixaban74$57,012
Abiraterone Acetate37$44,748
XareltoRivaroxaban32$25,326
Exemestane15$2,751
Letrozole128$2,537
Anastrozole102$1,050
Ondansetron Hcl30$713
Dexamethasone16$660
Prednisone84$334
Levothyroxine Sodium21$296
Lidocaine-PrilocaineLidocaine/Prilocaine20$285
Ondansetron OdtOndansetron17$266

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$125$316,50219 claims
AstraZenecaCalquence$86$267,64915 claims
Incyte CorporationJakafi$460$197,86911 claims
Johnson & JohnsonXarelto$127$25,32632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,855 nurse practitioner providers in Massachusetts.

Other nurse practitioner in Plymouth

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →